Syphilis
Also known as: Lues
Methodology & AI Transparency ⓘ
Syphilis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Syphilis is a sexually transmitted infection (STI) caused by bacteria.
- 2 Real-world patient consensus: Diagnostic registry A53.9: Syphilis is managed within Skin & Dermatology (aka Lues).
- 3 Typical cash cost range: Clinicians assessing Syphilis focus on cutaneous immune skewing in Syphilis (A53.9: (Th2/IL-4/IL-13 in atopic) and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Syphilis: Fasting Lipids & in Syphilis (A53.9: ALT (if systemic) (Within baseline reference limits (A53.9)) and 25-Hydroxy Vitamin D in Syphilis (A53.9: & hs-CRP).
Ask our AI Specialists anything about Syphilis
What Is Syphilis?
Syphilis is a sexually transmitted infection (STI) caused by bacteria. It infects the genital area, lips, mouth, or anus of both men and women. You usually get syphilis from sexual contact with someone who has it. It can also pass from mother to baby during pregnancy. The early stage of syphilis usually causes a single, small, painless sore. Sometimes it causes swelling in nearby lymph nodes. If you do not treat it, syphilis usually causes a non-itchy skin rash, often on your hands and feet. Many people do not notice symptoms for years. Symptoms can go away and come back. The sores caused by syphilis make it easier to get or give someone HIV during sex.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Syphilis (ICD-10 A53.9) is driven by cutaneous immune skewing in Syphilis (A53.9: (Th2/IL-4/IL-13 in atopic); Cross-referenced with NIH MeSH (Syphilis), specialists in Dermatology: Acne, Eczema, Psoriasis & Rosacea monitor 25-Hydroxy Vitamin D in Syphilis (A53.9: & hs-CRP) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Syphilis (A53.9): compromised epidermal barrier in Syphilis (A53.9: with dryness, fissuring,)
- • Secondary Syphilis clinical sign: post-inflammatory hyperpigmentation, facial in Syphilis (A53.9: flushing, or pitted)
- • Symptom flares in Syphilis correlating with Fasting Lipids & in Syphilis (A53.9: ALT (if systemic) deviation outside Within baseline reference limits (A53.9)
- • Functional skin & dermatology impact requiring clinical dermatologic lesion in Syphilis (A53.9: morphology exam) evaluation (A53.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Syphilis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | A53.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Fasting Lipids & in Syphilis (A53.9: ALT (if systemic) | Within baseline reference limits (A53.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Syphilis (A53.9: & hs-CRP) | 25(OH)D 40–65 ng/mL (A53.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Affected Body Surface in Syphilis (A53.9: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (A53.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Syphilis
Treatment selection for Syphilis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Syphilis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Irritation potential of tretinoin gel microsphere pump versus adapalene plus TGM 0.04% pump was associated with better facial tolerance as demonstrated by significantly less cumulative skin redness (P < 0.0001), dryness (P < 0.0001), burning/stinging (P < 0.0001) and itching (P < 0.0001) compared with... Journal of drugs in dermatology : JDD • 2010-08-15 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 20684151 ↗ |
| Can This Approach Help? Inside the Latest Research on Clinically meaningful improvements in cutaneous lesions and quality of life In this post-hoc analysis, nemolizumab-treated patients who had greater severe itching reductions also showed improvements in other eczema symptoms; severe itching alleviation appeared to be responsible for the improvements in... The Journal of dermatological treatment • 2023-12-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 36779675 ↗ |
Syphilis Patient Community & “People Like Me” Threads
Filter Syphilis community threads and patient logs by age, biological sex, dosage, and treatment duration.